Wyeth Duract launch ads claim superiority to Ultram, herald nonscheduled status.
Executive Summary
WYETH DURACT LAUNCH TOUTS SUPERIORITY TO J&J's ULTRAM in a six-page journal advertisement pre-cleared by FDA. The ad launching the non-steroidal anti-inflammatory drug appeared in the New England Journal of Medicine and the Journal of the American Medical Association. "More power than Ultram 100 mg...in a single-dose study of oral surgery," the ad states. The ad references an unpublished study comparing Duract (bromfenac), Ortho-McNeil's Ultram (tramadol) and placebo conducted by SciRex in Austin, Texas. The study was submitted with the NDA but was not included in Wyeth- Ayerst's Duract labeling. The ad footnotes that the data is on file at Wyeth.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: